Prevention of inflammasome activation by the use of IL1R inhibitors (e.g. anakinra) has been remarkably effective in several autoinflammatory diseases, most notably in cryopyrin-associated periodic syndromes (CAPS), gout and atherosclerotic disease [15, 44, 47, 52]. The gene discussed is IL1R1; the disease is cryopyrin-associated periodic syndrome.